TY - JOUR T1 - Preventing herpes zoster through vaccination: New developments JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 359 LP - 366 DO - 10.3949/ccjm.84a.16020 VL - 84 IS - 5 AU - Phuc Le AU - Camille Sabella AU - Michael B. Rothberg Y1 - 2017/05/01 UR - http://www.ccjm.org/content/84/5/359.abstract N2 - Herpes zoster (HZ) affects 1 million Americans every year. The disease burden is higher in immunocompromised patients. The live-attenuated HZ vaccine is effective in preventing HZ and postherpetic neuralgia and has been recommended for immunocompetent adults age 60 and older. However, because protection wanes by 10 years, a booster may be necessary. In 2015, an adjuvanted subunit HZ vaccine was shown to reduce incidence by 97%, even in the elderly, but long-term data on vaccine protection are not available. Clinical trials are under way to investigate a safe and effective vaccine for immunocompromised patients. ER -